
About this episode
We're starting to see some data on how well a two-dose vaccine series protects people from the omicron variant. It seems scary, but it actually might be hopeful? Meanwhile, Canada has been slow to scale up its booster shot program. Will the new variant give governments some urgency to move faster? And what about kids who just had their first dose or younger ones who haven't had any? How do they fare against the new variant?
GUEST: Sabina Vohra-Miller, clinical pharmacologist
We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:
Through email at [email protected]
Or @thebigstory.bsky.social on Bluesky
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time The Big Story publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Big Story

Big Headlines: Canada and the U.S. mourn 9/11 on the 25th anniversary of the ter...
The Big Story

What happened to our attention spans?
The Big Story

Big Headlines: Carney convenes his cabinet in Alberta and Trump vows American ad...
The Big Story

The age of technological imperialism
The Big Story